Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib trial investigates the side effects and best dose of pegcrisantaspase when
given together with fludarabine and cytarabine for the treatment of patients with leukemia
that has come back (relapsed) or has not responded to treatment (refractory).
Pegcrisantaspase may block the growth of cancer cells. Chemotherapy drugs, such as
fludarabine and cytarabine, work in different ways to stop the growth of cancer cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving pegcrisantaspase in combination with fludarabine and cytarabine may work better in
treating patients with leukemia compared to the combination of fludarabine and cytarabine.